51 results about "Cancer stem cell" patented technology

The present invention provides a compound with which a molecular probe capable of distinguishing NSCs from CSCs can be produced, and a method for detecting cancer stem cells using the compound. The present invention relates to a compound having a formyl group, a substrate moiety, a quenching moiety, and a luminescent moiety that is non-luminous due to the quenching moiety, wherein the luminescent moiety may be rendered luminous by detaching the substrate moiety by a substrate-degrading enzyme and also converting the formyl group to a carboxy group by an aldehyde dehydrogenase to allow the quenching moiety to dissociate.

The present invention relates to aptamers that specifically bind to the extra-cellular domain of alpha7 / beta1 integrin dimers, conjugates or particles comprising said aptamers, in muscles cells such as skeletal muscle fibres and satellite cells, or in cells aberrantly expressing said domain e.g. tumour cells such as rhabdomyosarcoma (muscle-derived tumours), or glioblastoma cancer stem cells, as well as conjugates comprising said aptamers, therapeutic or diagnostic compositions comprising said conjugates or said aptamers, and their use as a medicament and in diagnostic methods.

Disclosed are 1,2,4,5-tetraoxane compounds and derivatives thereof having anticancer properties. Disclosed are pharmaceutical compositions and pharmaceutical formulations in unit dosage form suitable for delivering the compounds to a subject in need thereof. In addition to the compounds, the pharmaceutical compositions or formulations can include one or more active agents, such as one or more additional anticancer agents. Also disclosed are methods of treating, mitigating, or treating or ameliorating one or more symptoms associated with cancer in a subject. The methods include (i) administering to a subject in need thereof an effective amount of a compound. The compound can be administered by oral administration, parenteral administration, inhalation, mucosal administration, or a combination thereof. The compound can selectively kill cancer cells and / or cancer stem cells, but not non-cancer cells, by inducing ferroptosis in the cancer cells and / or cancer stem cells.

This invention provides a method for diagnosing or treating cancerous diseases that contains cancer stem cells. [Solution] A method for measuring cancer stem cells is provided, comprising detecting cells expressing CLDN6. In particular, the present invention provides a method for measuring cancer stem cells, comprising detecting cells expressing CLDN6. Furthermore, the present invention provides a method for treating or preventing cancer, comprising inhibiting and / or eliminating cancer stem cells by administering an antibody having the ability to bind to CLDN6 to a cancer patient.

Provided herein are methods of detecting an aggression level of a glioblastoma in a subject. In some embodiments, the methods include imaging the subject having the glioblastoma using a CEST MRI technique in the absence of introducing an exogenous MRI contrast agent into the subject to produce a test MR image of the subject. In some embodiments, the methods also include identifying an overexpression level of mannose in and / or on surfaces of unlabeled cancer stem cells of the glioblastoma of the subject in the test MR image relative to an identified expression level of mannose in and / or on surfaces of brain cells in a control MR image, wherein a high aggression level is indicated when the overexpression level comprises at least about a 1.8-fold difference and wherein a low aggression level is indicated when the overexpression level comprises less than about a 1.8-fold difference. Related aspects are also provided.

Provided are methods relating to SIRPgamma as a biomarker for cancer cells, and in particular of cancer stem cells and lung adenocarcinoma. Disclosed are also methods of treatment, which involve administering a SIRPgamma targeted agent to a subject with cancer, alone or with another cancer therapy. Methods for diagnosing cancer, identifying subjects with high SIRPgamma levels for treatment, and monitoring SIRPgamma expressing tumors are also provided.

Provided herein are methods of detecting an aggression level of a glioblastoma in a subject. In some embodiments, the methods include imaging the subject having the glioblastoma using a CEST MRI technique in the absence of introducing an exogenous MRI contrast agent into the subject to produce a test MR image of the subject. In some embodiments, the methods also include identifying an overexpression level of mannose in and / or on surfaces of unlabeled cancer stem cells of the glioblastoma of the subject in the test MR image relative to an identified expression level of mannose in and / or on surfaces of brain cells in a control MR image, wherein a high aggression level is indicated when the overexpression level comprises at least about a 1.8-fold difference and wherein a low aggression level is indicated when the overexpression level comprises less than about a 1.8-fold difference. Related aspects are also provided.

The present invention relates to aptamers that specifically bind to the extra-cellular domain of alpha7 / beta1 integrin dimers, conjugates or particles comprising said aptamers, in muscles cells such as skeletal muscle fibres and satellite cells, or in cells aberrantly expressing said domain e.g. tumour cells such as rhabdomyosarcoma (muscle-derived tumours), or glioblastoma cancer stem cells, as well as conjugates comprising said aptamers, therapeutic or diagnostic compositions comprising said conjugates or said aptamers, and their use as a medicament and in diagnostic methods.

The present invention relates to a composition for the prevention or treatment of cisplatin-resistant cancer comprising an inhibitor of DUSP23 expression or activity as an active ingredient. It was found that DUSP23 expression is upregulated in cell clusters exhibiting characteristics of cancer stem cells, and that knocking down DUSP23 significantly reduces cell cluster formation as well as decreases the expression of SOX2, a major stem cell marker. Furthermore, DUSP23 expression was increased in lung cancer cells that had developed cisplatin resistance, and it was confirmed that the downregulation of DUSP23 inhibits self-renewal and invasive capabilities during the induction of cancer cell death. In addition, it was confirmed that DUSP23 plays an important role in promoting cancer stem cell characteristics through SOX2 expression. In conclusion, it has been shown that targeting DUSP23 can be a promising therapeutic strategy to overcome anticancer drug resistance in lung cancer, and the composition of the present invention is expected to be usefully utilized as a treatment for lung cancer cells with cisplatin resistance.

The present disclosure relates generally to compositions and methods for treating cancer. More specifically, the present disclosure relates to compositions and their use in one of altering the transformation of epithelial cells to mesenchymal cells or the transformation of mesenchymal cells to epithelial cells of tumor cells. The method comprises administering to the subject a composition comprising a PI3K inhibitor, such as paxalisib (GDC-0084), and an immunotherapy that is not targeted to cancer stem cells (CSC), wherein the immunotherapy is an immune checkpoint antagonist or a PARP inhibitor.

The present disclosure relates to compositions and methods for reducing cancer stem cells. In some aspects, the compositions and methods can comprise at least one metabolism modulating agent. In other aspects, the compositions and methods can comprise at least two metabolism modulating agents.

The present invention relates to novel antibodies or antigen-binding fragments thereof that specifically bind to TransMembrane 4 Superfamily Member 4 (TM4SF4). These antibodies or antigen-binding fragments thereof exhibit proliferation inhibitory activity of cancer cells so as to effectively prevent or treat cancer, and reduce the self-renewal ability of cancer stem cells to be usefully used even in the treatments of cancer with a poor prognosis in conventional anticancer treatments.

Provided herein are methods of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an agent that inhibits the activity of ZSCAN4 in cancer cells in the subject, thereby treating the cancer.

The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly cancer stem cells. Particularly, the invention relates to compounds of Formula I to XXII for the treatment of cancer.

Disclosed herein are methods of identifying gastric cancer stem cells or populations of gastric cancer stem cells. Also described herein are methods of isolating one or more gastric cancer stem cells from a population of cells, comprising contacting the cells of the population of cells with an AQP5-binding agent, isolating one or more AQP5-expressing cells bound to the agent, where the one or more AQP5-expressing cells are gastric cancer stem cells. Further described herein are methods of removing or eliminating AQP5 + gastric cancer stem cells as well as methods of treating gastric cancer and methods of monitoring gastric cancer neogenesis or gastric cancer progression.

To provide compositions and methods for using purified human RNA-editing enzymes.SOLUTION: In alternative embodiments, a method for eradicating or reducing the in vivo number of cancer stem cells is provided, where the method comprises administering an inhibitor of ADAR1 (adenosine deaminase associated with RNA1) to a subject in need thereof, where the ADAR1 inhibitor reduces or significantly reduces ADAR1 Nano-luc reporter activity in cell lines or in human cancer stem cell assays.SELECTED DRAWING: None

An object of the present invention is to provide a drug that suppresses the proliferation of cancer stem cells. Accordingly, it is an object to provide a composition and a method that can treat cancer, suppress cancer recurrence and suppress cancer metastasis. The above objects are achieved by a composition for suppressing proliferation of cancer stem cells comprising a triazolohalopyrimidine compound represented by the following general formula (I) as an active ingredient:

The present invention relates to a composition for inhibiting the growth of cancer stem cells and a use thereof. When treated with the EMP3 inhibitor, cancer stem cells expressing ALDH1 decrease in self-renewal potential, invasiveness, and migration ability and thus are restrained from growing, whereby cancer having stemness properties, which are resistant to conventional anticancer therapies, can be effectively treated.

Provided herein are compositions and methods for detecting presence of cancer cells, and treating the cancer cells, in a human, the method comprising: obtaining, or having obtained, a human tissue sample with cancer cells; and detecting in the human tissue sample for abnormalities in ribosome-associated quality control by detecting the presence of mitochondrial stress-induced protein carboxyl-terminal terminal alanine and threonine tailing (msiCAT-tailing) proteins, wherein the presence of msiCAT-tailing is indicative of the presence of cancer stem cells.

Compositions, methods, and uses of recombinant IL-8 antibodies, fragments thereof, or single-chain variable fragments (scFv) thereof with high affinity for IL-8 for targeting tumor-expressed or endogenous IL-8 are presented. Preferably, the recombinant IL-8 antibody or scFv fragment comprises a VFV comprising a first amino acid sequence selected from the group consisting of SEQ ID NOs: 1-15, 31-32. H segment, and / or a second amino acid sequence selected from the group consisting of SEQ ID NOs: 16-30, 33-34 L The recombinant IL-8 antibody or scFv fragment can be formulated as a pharmaceutical composition for administration to tumor-bearing patients to reduce tumor metastasis, reduce immunosuppression in the tumor microenvironment, or reduce a Th2-mediated immune response.

The present invention relates to an antibody or antigen-binding fragment thereof specific for transmembrane and coiled domain family 3 (TMCC3). The invention also relates to a pharmaceutical composition for treating and / or preventing a disease associated with a TMCC3-mediated signal in a subject in need thereof, and a method for detecting TMCC, cancer stem cells or cancer in a sample.

Disclosed are compounds, nanoparticles, and compositions for effective delivery of metabolic inhibitors to disease state cells. Also disclosed are methods of treating a subject in need thereof, such as a subject with cancer.

The present invention provides methods and kits a) for preventing and / or treating neuroblastoma (e.g., high-risk neuroblastoma) that is linked, in part, to high levels of ODC activity and increased cellular polyamine content, b) for predicting cancer patient survival, especially cancer patients whose cancer is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and c) for selecting treatment options for such patients based on the allelic nucleotide sequence or SNP at positions +263 and / or +316 of the ODC1 gene. The invention also provides, cancer treatment methods comprising the determination of the ODC1 genotype at the +263 and / or +316 positions, as a means to guide treatment selection, which includes, in some aspects the administration of pharmaceutically effective amounts of α-difluoromethylornithine (DFMO), either as a monotherapy or in combination with one or more other drugs. In addition, the present invention provides methods for preventing and / or treating patients that have been determined to have cancer stem cells, such as patients in cancer remission that are at risk for relapse.

Disclosed is the in vitro use of at least one lectin which recognises the fucose alpha(1-2) galactose unit for labelling cancer stem cells of organs involved in respiration, in order to obtain labelled cancer stem cells of organs involved in respiration, in a biological sample. In one particular embodiment, the at least one lectin is chosen from the lectins Ulex Europaeus agglutinin 1 (UEA-1) or the homologue thereof, Trichosanthes japonica agglutinin II (TJA-II), Agaricus Bisporus agglutinin (ABA), Amaranthus Caudatus agglutinin (ACA), jacalin, Griffonia Simplicifolia lectin I (GSL-I) and Griffonia Simplicifolia lectin II (GSL-II). In one particular embodiment, the organ involved in respiration is chosen from the lungs, the larynx, the pharynx, the mouth, the nose, the throat, the tongue, the sinuses, the trachea and the saliva glands including the tonsils and the parotid gland.

Disclosed herein are compositions and methods related to a plurality of stem cells administered a TGF-beta pathway inhibitor and / or a Hippo pathway inhibitor. In some embodiments, the composition does not comprise a gel matrix and / or either mesenchymal stem cells or cancer stem cells. In some embodiments, at least 25% of the cells in the composition are dissociated. In some embodiments, the stem cells are agitated in the composition.

The present invention relates to a composition for inhibiting the growth of cancer stem cells, and a use thereof. A WDR34 inhibitor of the present invention inhibits the conversion of cancer cells into cancer stem cells and exhibits activity of inhibiting self-renewal, invasion, and migration of cancer stem cells, and thus can be effectively used as a cancer cell growth or metastasis inhibitor or a cancer stem cell growth inhibitor.

The present application relates to methods and uses of conjugates comprising antitumor agents (e.g., chemotherapeutic agents) conjugated to peptide compounds targeting Sortilin-expressing cancer stem cells (CSCs), in embodiments for the treatment of poor prognosis cancers refractory to standard antitumor therapies associated the presence of Sortilin-expressing CSCs, and for preventing or treating cancer relapse or recurrence.

The present invention relates to cancer cell-specific antibodies and uses thereof. According to one aspect, antibodies specific for membrane proteins of cancer stem cells or cancer cells exhibit a strong affinity for ITGA3 or VLA3 and excellent cellular internalization, therefore, the present invention can be effectively used in the diagnosis, treatment or research on the development of therapeutic agents for various cancers in the form of unconjugated antibodies, antibody-drug conjugates (ADCs), and other antibody complexes based on the antibodies.

Disclosed herein are compounds and pharmaceutical compositions comprising the compounds that inhibit ENL / AF9YEATS and FLT3. Also disclosed are methods of using the compounds and pharmaceutical compositions comprising the compounds to inhibit oncogene expression in cells or to treat acute leukemia. The compounds, pharmaceutical compositions and methods are useful for inhibiting cancer and key driver factors for cancer stem cell survival.

The present invention provides methods comprising conjointly administering a cannabinoid, a probiotic composition, IL-15, or any combination thereof, e.g., for inhibiting growth of cancer stem cells and activating NK cells. This invention also provides methods of treating cancer comprising cancer stem cells by administering one or more of these therapies to patients in need thereof.